The role of S100A4 for bone metastasis in prostate cancer cells by Kim, Bongjun et al.
RESEARCH ARTICLE Open Access
The role of S100A4 for bone metastasis in
prostate cancer cells
Bongjun Kim1,2†, Suhan Jung1†, Haemin Kim3, Jun-Oh Kwon1, Min-Kyoung Song1, Min Kyung Kim1,
Hyung Joon Kim4 and Hong-Hee Kim1*
Abstract
Background: Prostate cancers frequently metastasize to bone, where the best microenvironment for distant
colonization is provided. Since osteotropic metastasis of prostate cancer is a critical determinant of patients’ survival,
searches for preventive measures are ongoing in the field. Therefore, it is important to dissect the mechanisms of
each step of bone metastasis, including the epithelial-mesenchymal transition (EMT) and cross-talk between
metastatic niches and cancer cells.
Methods: In this study, we established a highly bone-metastatic subline of human prostate cancer cells by
selecting bone-homing population of PC3 cells after cardiac injection of eight-week-old male BALB/c-nude mice.
Then we assessed the proliferation, EMT characteristics, and migration properties of the subline (mtPC3) cells in
comparison with the parental PC3 cells. To investigate the role of S100A4, we performed gene knock-down by
lentiviral transduction, or treated cells with recombinant S100A4 protein or a S100A4-neutralizing antibody. The
effect of cancer cells on osteoclastogenesis was evaluated after treatment of pre-osteoclasts with conditioned
medium (CM) from cancer cells.
Results: The mtPC3 cells secreted a markedly high level of S100A4 protein and showed elevated cell proliferation
and mesenchymal properties. The increased proliferation and EMT traits of mtPC3 cells was inhibited by S100A4
knock-down, but was not affected by exogenous S100A4. Furthermore, S100A4 released from mtPC3 cells
stimulated osteoclast development via the cell surface receptor RAGE. Down-regulation or neutralization of S100A4
in the CM of mtPC3 cells attenuated cancer-induced osteoclastogenesis.
Conclusion: Altogether, our results suggest that intracellular S100A4 promotes cell proliferation and EMT
characteristics in tumor cells, and that secreted S100A4 activates osteoclastogenesis, contributing to osteolytic bone
metastasis. Thus, S100A4 upregulation in cancer cells highly metastatic to bone might be a key element in
regulating bone metastasis.
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Background
An aging population with increasing prevalence of pros-
tate cancer (PC) has become a global health care chal-
lenge [1]. PC predom [2] inantly metastasizes to bone,
and treatment of bone metastasis has been a major con-
cern over several decades [1]. Typically, bone metastasis
of PC forms osteoblastic lesions; however evidence sug-
gests that osteolytic components also contribute to
tumor growth in bone [2, 3]. The osteolytic nature of PC
bone metastasis arises from cross-talk between tumor
cells and normal bone cells. Metastatic cells in the bone
microenvironment support osteoclast activation directly
or indirectly by inducing factors such as RANKL, the
most potent osteoclastogenic factor, in osteoblasts [4].
In support of this notion, tumor-secreted molecules such
as parathyroid hormone-related peptide (PTHrP) and
interleukin 8 (IL-8) enhance osteoclast-mediated bone
resorption, thereby increasing the local availability of
bone matrix storage proteins such as transforming
growth factor-β (TGF-β) [5]. Subsequently, the increas-
ing concentration of TGF-β perpetuates tumor growth
in the bone, leading to a vicious cycle between tumor
and bone [4]. This emphasizes the role of osteoclasts in
releasing tumor growth factors from the bone matrix; in
addition, recent studies have shown that dormant tumor
cells in the bone microenvironment are re-activated by
osteoclasts [6, 7]. Based on these findings, unveiling
cross-talk between tumor cells and osteoclasts is a valid
approach to find a cure for bone metastasis.
The metastasis of cancer involves epithelial-
mesenchymal transition (EMT), one of the crucial steps
in cancer metastasis, at the primary site [8]. During
EMT progression, the transcription factor SNAI1 dir-
ectly represses E-cadherin, resulting in the loss of epithe-
lial properties [9], while the expression levels of proteins
with mesenchymal features, such as N-cadherin and
vimentin, are up-regulated [10]. PC metastasis engages
EMT for successful colonization of distant organs includ-
ing bone [2, 11, 12]. Several lines of evidence have re-
vealed that epithelial-mesenchymal plasticity plays a
pivotal role in both PC metastasis and drug-resistance [13,
14]. Therefore, our understanding of EMT mechanisms
should be deepened to overcome bone metastasis in PC.
S100 calcium-binding protein A4 (S100A4) is a mem-
ber of the S100 calcium-binding protein family, which
plays a crucial role in the progression of cancer metasta-
sis [15, 16]. S100A4 has been reported to mediate
proliferation, migration, invasion, and apoptosis in many
types of tumor cells, including prostate cancer cells [16,
17]. Because of its presence in both intracellular and
extracellular regions of tumor cells, its molecular func-
tion has been studied in various experimental settings.
Intracellular S100A4 interacts with liprin, ezrin, and
non-muscle myosin II to promote cytoskeleton
rearrangement, which mediates cell migration and inva-
siveness [18–20]. In addition, S100A4 binds with p53, a
tumor suppressor, interrupting its DNA binding activity
[21]. The extracellular function of S100A4 also supports
tumor progression. Extracellular S100A4 has been
shown to induce angiogenesis, neurite outgrowth, and
migration of astrocytic tumor cells [22–24]. In particu-
lar, S100A4 interacts with receptor for advanced
glycation end products (RAGE) on the surface of cells to
increase the invasive potential of melanoma, thyroid
cancer cells, and colorectal cancer cells [25–27]. Re-
cently, we have reported that S100A4 promotes osteo-
lytic bone metastasis in breast cancer by regulating cell
migration and osteoclastogenesis [28]. However, the mo-
lecular mechanisms of S100A4 in the progression of PC
bone metastasis remains unclear. Moreover, the role of
S100A4 in cross-talk between prostate cancer cells and
bone cells has not been investigated to date.
In this study, we obtained a highly bone-metastatic
subline of human prostate cancer cells using an in vivo
selection method. Elevated S100A4 in this bone-
metastatic subline promoted proliferation and EMT
traits by intracellular functions, and cell migration to
some extent through extracellular mechanisms. More-
over, S100A4 release from this bone-metastatic PC stim-




Animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of Seoul
National University. All the animals were kept in an SPF
facility with consistent temperature (22 °C) and humidity
(55%), and a 12-h light/dark cycle. The facility was oper-
ated by experienced zookeepers who were responsible
for serving bedding material, food, and sterilized water,
under the supervision of a veterinarian. 4 to 5 mice were
housed in each cage. All the animals had free access to
food and water. All mice were sacrificed by carbon diox-
ide asphyxiation as approved by the IACUC of Seoul
National University. Five-week-old female ICR mice and
eight-week-old male BALB/c-nude mice were purchased
from OrientBio (Sungnam, Korea). ICR (n = 5) mice
were used for bone marrow cell preparation. Bone
marrow-derived macrophages were prepared as previ-
ously described [29]. Bone-metastatic cancer selection
was described in our earlier publication [28]. The bone-
metastasis rate of cancer cells by intra cardiac injection
was approximately 20% in our previous study. Thus we
used five mice for bone-metastatic cancer selection.
Briefly, left ventricular cardiac injection was performed
with 1 × 105 PC3 cells injected into nine-week-old male
BALB/c-nude mice (n = 5). After 8 weeks, metastasized
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cells in femurs and tibiae were flushed out from the
bone marrow and expanded in culture dishes for 8
weeks. Then, the immortal cells were re-injected into
the left ventricle for another round of in vivo selection
(n = 5). We named the cancer cells harvested after the
second round the mtPC3 cells. Each purpose of experi-
ment was to obtain primary cells or bone-metastasized
cancer cell. No control group was used.
Reagents
Recombinant M-CSF and RANKL were purchased from
PeproTech. Recombinant mouse S100A4 was purchased
from Prospec. Recombinant OPG was purchased from
R&D Systems. Antibodies against vimentin and c-Fos
were purchased from Santa Cruz. Antibodies against N-
cadherin and snail2 were obtained from Cell Signaling
Technology. Antibodies for RAGE (DD/A11) were from
Millipore. Anti-S100A4 antibody was purchased from
Abcam. Anti-β-catenin antibody was purchased from
Invitrogen. Antibodies for NFATc1 (7A6), E-cadherin,
and hHLA were purchased from BD Pharmingen. Anti-
β-actin antibody (AC-74) and the leukocyte acid phos-
phatase kit (for TRAP staining) were purchased from
Sigma-Aldrich. Lipofectamine for siRNA transfection
was purchased from Life Technologies. siRNA oligonu-
cleotides and shRNA lentiviral particles were purchased
from Santa Cruz. Dentin slices were purchased from Im-
munodiagnostic Systems.
Cell lines and culture conditions
LNCaP and PC3 cells were purchased from the Korean
Cell Line Bank (Seoul, Korea). Cell lines were validated
by STR-PCR analysis by the Korean Cell Line Bank, and
the STR profiles of each cell line can be accessed from
their website (https://cellbank.snu.ac.kr/main/tmpl/sub_
main.php?m_cd=22&m_id=0503). Cells were cultured in
high-glucose DMEM (Lonza) supplemented with 10%
FBS (Life Technologies) and 1% penicillin and strepto-
mycin (WELGENE, Korea).
Flow cytometry
mtPC3 cells were authenticated by labelling with PE-
conjugated mouse anti-human β2-microglobulin (BD
Pharmingen). Human β2-microglobulin is associated
with the HLA Class I antigen complex. During flow cy-
tometry analyses, mouse bone marrow cells served as a
negative control and human embryonic kidney-293 cells
were utilized as a positive control. Briefly, 1 × 105 cells
were incubated with the antibody (1:100) for half an
hour and softly washed with ice-cold PBS three times
before analysis using FACSCalibur (BD Science).
Western blotting
Cells were washed with ice-cold PBS and lysed with
RIPA buffer (10 mM Tris pH 7.2, 150 mM NaCl, 0.1%
sodium dodecyl sulfate, 1% Triton X-100, 1% sodium
deoxycholate, and 5 mM ethylenediaminetetraacetic
acid). A standard protocol for Western blotting was per-
formed with cell lysates.
Cell proliferation assay
Cells were incubated at the indicated time with 10%
CCK solution in cell culture medium for 1 h at 37 °C.
Optical density was then measured with an ELISA
reader (iMARK Microplate Absorbance Reader, Bio-Rad,
Hercules, CA, USA) at 450 nm.
Cell migration assay
The cell migration assay was performed using trans-well
plates with 8.0-μm polycarbonate membranes (Corning).
1 × 105 cancer cells were seeded onto the upper cham-
ber. The cells were tested for the migration toward the
lower chamber during stimulation by serum with or
without S100A4 (2 μg/ml) or S100A4 neutralizing anti-
bodies (4A, 30 μg/ml). After 16 h, migrated cells were
fixed with fixing solution, followed by crystal violet
staining for visualization with a microscope (Olympus
BX51, 20x objective lenses, DP72 camera, DP2-BSW
software (version 2.2)).
Conditioned medium preparation
1 × 106 cancer cells were seeded onto a 60-mm culture
dish with DMEM and incubated overnight. The next
day, the culture medium was exchanged to alpha-MEM
(WELGENE) and further incubated for 24 h. Then, the
supernatant was collected and centrifuged at 1200 rpm
to remove dead cells. A 3:7 (supernatant to fresh
medium) ratio was used unless specifically indicated in
the figure legend.
Osteoclast differentiation
BMMs were prepared from 5-week-old female ICR mice
as previously described [29]. Pre-osteoclasts were gener-
ated by culturing BMMs with M-CSF (30 ng/mL) and
RANKL (50 ng/mL) for 36 to 48 h. Then, mature osteo-
clast formation was induced by incubating pre-
osteoclasts with M-CSF (30 ng/mL) and conditioned
medium from cancer cells. Multinucleated TRAP+ cells
usually formed within 24 to 48 h after conditioned
medium treatment. TRAP+ cells with 3 or more nuclei
were visualized under a microscope and considered to
be mature osteoclasts (Olympus BX51, 20x objective
lenses, DP72 camera, DP2-BSW software (version 2.2)).
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Real-time PCR analysis
A standard protocol for real-time PCR analysis was
pursued for the quantification of mRNA levels. Primers
for real-time PCR analyses are as follows: human hprt
(hypoxanthine-guanine phosphoribosyltransferase)
forward, 5′- accccacgaagtgttggata-3′; human hprt reverse,
5′- aagcagatggccacagaact-3′; human s100a4 forward, 5′-
gcccagcttcttggggaaaa-3′; human s100a4 reverse, 5′-
atggcgatgcaggacaggaa-3′.
Enzyme-linked immunosorbent assay (ELISA)
1 × 105 cancer cells/well were seeded onto a 48-well tis-
sue culture plate and incubated overnight. The culture
medium was replaced with 100 μL serum-free medium
and further incubated for 24 h. Supernatant was col-
lected and subjected to ELISA with a human S100A4
ELISA kit (CycLex Co.) according to the manufacturer’s
protocol.
Osteoclast resorption assay
A dentin slice was placed into each well of a 48-well
tissue culture plate, after which 4 × 104 BMMs were
seeded as well. Osteoclast differentiation and bone re-
sorption were induced by supplementing M-CSF (30 ng/
mL) and RANKL (50 ng/mL). Dentin slices were washed
with distilled water for cell removal and mounted on
glass slides. The resorbed depth and area were calculated
by inspecting the dentin surface using a Zeiss LSM 5
PASCAL laser-scanning microscope (20x objective
lenses; Carl Zeiss Microimaging GmbH, Goettingen,
Germany). The Zeiss LSM Image Browser program was
utilized (version 3.0 SP3).
Gene knockdown
S100A4 and control shRNA lentiviral particles were
purchased from Santa Cruz Biotechnology, Inc. mtPC3
cells were transduced with lentiviral particles and incu-
bated for 2 days. The cells were incubated with puro-
mycin (10 μg/mL) for an additional 3 days to sort the
successfully transduced cells. For siRNA transfection,
BMMs were seeded in the presence of M-CSF (30 ng/
mL) and incubated overnight. The next day, Lipofecta-
mine 2000 (Invitrogen) was used for the formation of
the liposome complex containing siRNAs. The complex
was incubated with BMMs for 6 h, followed by fresh
media replacement.
GEPIA analysis
S100A4 expression patterns across various human can-
cer were analyzed using GEPIA, an online tool for The
Cancer Genome Atlas (TCGA) and Gene Tissue Expres-
sion (GTEX) databases [30]. Furthermore, the GEPIA
survival analysis was used to verify the relationship be-
tween S100A4 expression and prostate cancer prognosis.
The correlation of gene expression was evaluated using
Spearman’s correlation analysis.
Statistics
Data are presented as the mean ± SD of biological
replicates. An unpaired two-tailed Student’s t-test was
used to define differences between two samples. One-
way ANOVA or Two-way ANOVA with a post hoc
Bonferroni or Tukey’s test were used for analyses of
multiple groups. All statistical tests were performed
using SigmaPlot 11.0 (Version 11.2.0.11, Systat software
Inc., San Jose, CA, USA). p < 0.05 was considered statis-
tically significant.
Results
S100A4 is up-regulated in bone-metastatic prostate
cancer cells
To obtain bone-metastasized prostate cancer cells, we
performed an in vivo selection experiment previously
described for collecting highly bone-metastatic breast
cancer cells [28]. Human prostate cancer PC3 cells were
inoculated into the left ventricle of immune compro-
mised Balb-c/nu mice, and 8 weeks later whole bone
marrow cells were flushed from the long bones. Then,
the cells were cultured for 2 months in vitro to remove
mortal cells. The remaining cells were re-injected into
mice. After 8 weeks, bone marrow cells were harvested
and cultured again for 2 months. The cells obtained after
the second round of selection were verified to be
homogenous human cells by flow cytometry with anti-
human β2-microglobulin antibody (Fig. 1a). We named
this subline of PC3 cells mtPC3 cells (bone-metastasized
PC3 cells). Next, we assessed the expression levels of
S100A4 in the mtPC3 line. mtPC3 cells showed signifi-
cantly higher mRNA expression levels of S100A4
compared to their parent cells (Fig. 1b). Western blot-
ting of cell lysates revealed that the intracellular protein
level of S100A4 was also markedly elevated in mtPC3
cells (Fig. 1c). We next tested whether the S100A4 pro-
tein was secreted from the cells by performing a human
S100A4 ELISA with conditioned medium (CM) of can-
cer cells. While S100A4 was almost undetectable in
LNCaP and PC3 cell CM, the concentration of S100A4
was as high as 51.4 ± 2.04 ng/ml in mtPC3 CM (Fig. 1d).
Altogether, these results indicate that bone-metastatic
prostate cancer cells express high levels of S100A4
mRNA and protein, and secrete a greatly elevated level
of S100A4 protein into the extracellular milieu.
Intracellular S100A4 increases cell proliferation of bone-
metastatic prostate cancer
Previous reports have shown that S100A4 regulates cell
growth in a context-dependent manner [31, 32]. Thus, we
examined the potential role of S100A4 in the proliferation
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of mtPC3 cells utilizing lentiviral transduction of S100A4
shRNA. Western blotting of whole cell lysates (Fig. 2a)
and ELISA of culture supernatants (Fig. 2b) demonstrated
successful down-regulation of S100A4 by shRNA. The
mtPC3 cells with S100A4 shRNA (mtPC3-S) showed sig-
nificantly lower proliferation compared to mtPC3 cells
with control shRNA (mtPC3-C) (Fig. 2c). We next tested
whether the proliferation of mtPC3 cells was regulated by
intracellular or secreted S100A4. Interestingly, recombin-
ant human S100A4 (rhS100A4) did not affect the prolifer-
ation of either mtPC3-C or mtPC3-S cells (Fig. 2d). In
addition, the proliferation of both mtPC3-C and mtPC3-S
cells was not altered by treatment with an S100A4-
neutralizing antibody, 4A [28] (Fig. 2e). The effect of
extracellular S100A4 on proliferation was also not ob-
served with LNCaP and PC3 cells (Supplementary Fig. 1).
Taken together, these data indicate that S100A4 promotes
proliferation of bone-metastatic prostate cancer cells by
an intracellular mechanism.
S100A4 promotes EMT traits and migration of prostate
cancer cells
Since prostate cancer metastasis involves EMT [11, 12],
we investigated whether mtPC3 cells underwent EMT
by assessing protein levels of epithelial (E-cadherin and
β-catenin) and mesenchymal (N-cadherin, snail2, and
vimentin) markers. Western blot analysis demonstrated
that the non-metastatic LNCaP prostate cancer cell line
highly expressed E-cadherin and β-catenin, but not N-
cadherin, snail2, or vimentin, indicating the epithelial
characteristics of this cell line (Fig. 3a). PC3 cells
expressed E-cadherin and β-catenin to a lesser extent
than LNCaP and showed evident expression of N-
cadherin, snail2, and vimentin, depicting both epithelial
and mesenchymal characteristics (Fig. 3a). The mtPC3
cells showed a negligible amount of E-cadherin and β-
catenin but had significant levels of vimentin, demon-
strating the most mesenchymal characteristic among the
three cell types tested (Fig. 3a). Consistent with mesen-
chymal characteristics, mtPC3 cells showed the highest
cell migration capacity (Fig. 3b). Thus, we evaluated
whether S100A4 affects cell migration and EMT. As
shown in Fig. 3c, mtPC3-S cells showed significantly in-
creased expression of E-cadherin and β-catenin and
lower levels of N-cadherin compared to mtPC3-C cells
(Fig. 3c). Although protein levels of vimentin and snail2
were not affected by S100A4 shRNA (Fig. 3c), these data
indicate that mtPC3 cells lost some mesenchymal
Fig. 1 S100A4 expression and secretion is elevated in bone-metastatic prostate cancer cells. a Flow cytometry with anti-human β2-microglobulin
Ab verified these bone-metastatic PC3 cells (mtPC3s) as human cells. Neg. Cont., mouse bone marrow cells; Pos. Cont., HEK-293 cells. b S100A4
mRNA expression in LNCaP, PC3, and mtPC3 cells was analyzed with real-time PCR. n = 3 per group. c S100A4 protein expression in LNCaP, PC3,
and mtPC3 cells was analyzed by western-blotting. d Levels of S100A4 protein secretion in LNCaP, PC3, and mtPC3 cells in cell culture medium
were measured by ELISA. n = 3 per group. ***p < 0.001 by one-way ANOVA with post hoc Tukey’s test. Data are presented as the mean ± SD. The
full-length gels are presented in Supplementary Fig. 3a
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characteristics through S100A4 knock-down. Consistent
with this proposition, mtPC3-S cells showed decreased
cell migration compared to mtPC3-C cells (Fig. 3d).
As the effect of S100A4 knock-down could be attrib-
uted to altered levels of intracellular and/or extracellular
S100A4, we next sought to dissect the role of intracellu-
lar versus extracellular S100A4 on EMT and migration
in mtPC3 cells. To evaluate the function of extracellular
S100A4, we treated mtPC3-C and mtPC3-S cells with
rhS100A4 and assessed the levels of EMT marker pro-
teins. rhS100A4 did not change the expression levels of
E-cadherin, β-catenin, or N-cadherin in mtPC3-S cells;
however, it slightly increased E-cadherin and β-catenin
expression in mtPC3-C cells (Fig. 4a). In addition, the
S100A4-neutralizing antibody 4A did not alter E-
cadherin, β-catenin, or N-cadherin expression in
mtPC3-C or mtPC3-S cells (Fig. 4a). As the mtPC3 cells
had already undergone EMT and possessed mesenchy-
mal properties, it is possible that exogenous treatment of
rhS100A4 or neutralizing antibody does not affect
mtPC3 characteristics, even if EMT of mtPC3 cells were
driven by extracellular S100A4. Thus, we investigated
whether rhS100A4 influences EMT of LNCaP and PC3
cells which have relatively more epithelial properties.
The levels of EMT markers were not changed by
rhS100A4 in both cells (Fig. 4b). These results indicate
that EMT in mtPC3 cells is regulated by intracellular,
not extracellular, S100A4. Interestingly, cell migration of
mtPC3-S cells was partially rescued by rhS100A4 (Fig.
4c), and 4A decreased mtPC3-C cells migration (Fig.
4d). Taken together, these data suggest that EMT of
mtPC3 cells is enhanced by intracellular S100A4, while
cell migration is promoted by both intracellular and
extracellular S100A4.
S100A4 mediates bone-metastatic prostate cancer-
induced osteoclastogenesis via RAGE
We next investigated whether S100A4 secreted from
mtPC3 cells affects osteolysis. We used mouse primary
bone marrow-derived macrophages (BMMs) for osteo-
clastogenesis. CM from PC3 and mtPC3 cells were ap-
plied to pre-osteoclasts (pOCs) generated by priming
BMMs with RANKL. The mtPC3 CM enhanced the
number of mature tartrate-resistant acid phosphatase-
positive (TRAP+) multinucleated cells (osteoclasts; OCs)
compared with the CM from PC3 cells (Fig. 5a). Because
RANKL is an essential factor for osteoclastogenesis, we
tested whether osteoprotegerin (OPG, an RANKL antag-
onist) could inhibit the effect of mtPC3 CM. Surpris-
ingly, OPG treatment only partially reduced
Fig. 2 Intracellular S100A4 promotes proliferation of bone-metastatic prostate cancer cells. a, b Lentiviral transduction of S100A4 shRNA efficiently
reduced S100A4 protein levels in mtPC3 cells (a) as well as S100A4 protein secretion in culture medium from mtPC3 cells (b). ***p < 0.001 by
unpaired two-tailed Student’s t-test. c-e Proliferation of mtPC3 cells with control shRNA (mtPC3-C) vs. S100A4 shRNA (mtPC3-S) was analyzed with
the CCK kit (c). Proliferation of mtPC3-C or mtPC3-S cells in the presence of BSA or recombinant human S100A4 (S100A4; 2 μg/ml) was analyzed
with the CCK kit (d). Proliferation of mtPC3-C or mtPC3-S cells in the presence of control antibody or monoclonal anti-S100A4 antibody (4A;
30 μg/ml) was analyzed with the CCK kit (e). ***p < 0.001 by two-way ANOVA with post hoc Bonferroni’s test. N.S., not significant. Data are
presented as the mean ± SD. The full-length gels are presented in Supplementary Fig. 3b
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osteoclastogenesis, suggesting that RANKL was not the
sole factor triggering osteoclastogenesis in mtPC3 CM
(Fig. 5b). We next compared the effect of CM from
mtPC3-C and mtPC3-S cells to evaluate the role of se-
creted S100A4 in stimulating osteoclastogenesis. As
shown in Fig. 5c and d, CM from mtPC3-C cells suc-
cessfully induced differentiation and resorption activity
of OCs (Fig. 5c and d). However, the CM from mtPC3-S
cells only weakly induced osteoclast formation and bone
resorption (Fig. 5c and d). Protein levels of c-Fos and
NFATc1, key transcription factors for osteoclastogenesis,
were consistently lower in pOCs treated with CM from
mtPC3-S cells compared to those treated with CM from
mtPC3-C cells (Fig. 5e). Moreover, neutralization of
S100A4 with 4A Ab inhibited mtPC3 CM-induced
osteoclastogenesis in a dose-dependent manner (Fig.
5f). Collectively, these results suggest that bone-
metastatic prostate cancer-derived S100A4 stimulates
osteoclastogenesis.
S100A4 protein has been shown to bind the cell sur-
face receptor RAGE, mediating tumor cell survival and
metastasis [16]. Our previous study on bone-metastatic
breast cancer showed that RAGE plays a crucial role in
S100A4-stimulated osteoclastogenesis [28]. Therefore,
we assessed whether bone-metastatic prostate cancer
also utilizes RAGE for osteoclast development. A loss
of function approach using RAGE-targeting siRNA led
to successful down-regulation of RAGE in BMMs at the
protein level (Fig. 6a). RAGE knock-down significantly
reduced osteoclast differentiation in cells treated with
Fig. 3 S100A4 promotes cell migration and EMT of bone-metastatic prostate cancer cells. a Protein levels of E-cadherin, β-catenin, N-cadherin,
Snail2, Vimentin, and β-actin in LNCaP, PC3, and mtPC3 cells were determined by western blotting with the indicated antibodies. b Cell migration
of LNCaP, PC3, and mtPC3 cells was measured by transwell assay. Representative images (left panels) and quantification of migrated cells (right
panel). Scale bar = 100 μm. ***p < 0.001 by one-way ANOVA with post hoc Tukey’s test. c Protein levels of E-cadherin, β-catenin, N-cadherin,
Snail2, Vimentin, and β-actin in mtPC3-C or mtPC3-S cells were determined by western blotting with the indicated antibodies. d Cell migration of
mtPC3-C or mtPC3-S cells was measured by transwell assay. Representative images (left panels) and quantification of migrated cells (right panel).
Scale bar = 100 μm. ***p < 0.001 by unpaired two-tailed Student’s t-test. Data are presented as the mean ± SD. The full-length gels are presented
in Supplementary Fig. 3c and 3d
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mtPC3-C-CM, while osteoclast formation with mtPC3-
S-CM was not significantly different between the con-
trol knock-down and RAGE knock-down groups (Fig.
6b). In addition, bone resorption in mtPC3-CM-treated
culture was significantly decreased by RAGE knock-
down (Fig. 6c). Protein expression of c-Fos and
NFATc1 upregulated by mtPC3-CM were consistently
attenuated by RAGE knock-down (Fig. 6d). Taken to-
gether, our data show that S100A4 secreted from bone-
metastatic prostate cancer interacts with RAGE on
osteoclast precursor cells to accelerate osteoclast
development.
Fig. 4 S100A4 promotes EMT and cell migration of bone-metastatic prostate cancer cells. a, mtPC3-C or mtPC3-S cells were cultured in the
presence of BSA, S100A4 (2 μg/ml), control antibody, or 4A (30 μg/ml) for 48 h, and then protein levels of E-cadherin, β-catenin, N-cadherin, and
β-actin were determined by western blotting with the indicated antibodies. b The protein levels of E-cadherin, β-catenin and N-cadherin were
analyzed by western blotting with lysates from LNCaP and PC3 cells cultured in the presence of BSA or S100A4 (2 μg/ml) for 48 h. c Cell
migration of mtPC3-C or mtPC3-S cells was measured by transwell assay in the presence of BSA or S100A4 (2 μg/ml). Representative images (left
panels) and quantification of migrated cells (right panel). Scale bar = 100 μm. d Cell migration of mtPC3-C or mtPC3-S cells was measured by
transwell assay in the presence of control antibody or 4A (30 μg/ml). Representative images (left panels) and quantification of migrated cells
(right panel). Scale bar = 100 μm. *p < 0.05 and ***p < 0.001 by one-way ANOVA with post hoc Tukey’s test. Data are presented as the mean ± SD.
The full-length gels are presented in Supplementary Fig. 3e and 3 f
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Discussion
In this study, we found that S100A4 is up-regulated in
bone-metastatic prostate cancer cells, the mtPC3 cells
(Fig. 1). We observed that S100A4-high mtPC3 cells ex-
hibited more mesenchymal characteristics than their
parent cells (Fig. 3). This mesenchymal phenotype was
decreased by S100A4 knock-down, but was not altered
by recombinant S100A4 or S100A4-neutralizing anti-
bodies (Fig. 4). Cell proliferation of mtPC3 was also
decreased by S100A4 knock-down, but not by exogenous
S100A4 treatment or S100A4 neutralization (Fig. 2).
Moreover, we found that mtPC3-CM stimulated
osteoclastogenesis, which was attributed to elevated
secretion of S100A4 from mtPC3 cells (Fig. 5). Similarly,
shRNA-mediated knockdown or administration of
S100A4-neutralizing antibody nullified the enhanced
osteoclastogenesis induced by mtPC3-CM (Fig. 5). Fur-
thermore, we observed that RAGE on the surface of pre-
Fig. 5 Bone-metastatic prostate cancer cells promote osteoclastogenesis by secretion of S100A4. a Pre-osteoclasts (pOCs) received PC3- or
mtPC3-CM and were then tested for osteoclast generation. Representative tartrate-resistant acid phosphatase (TRAP)-stained images (left panels)
and quantification of TRAP+ multinucleated cells (MNCs) with 3 or more nuclei (right panel). Scale bar = 100 μm. ***p < 0.001 by unpaired two-
tailed Student’s t-test. b pOCs were treated with 30% PC3-CM or mtPC3-CM with BSA or OPG (100 ng/mL). Representative TRAP-stained images
(left panel) and quantification of TRAP+ MNCs (right panel). Scale bar = 100 μm. ***p < 0.001 by one-way ANOVA with post hoc Tukey’s test. c
pOCs receiving the indicated percentages of CM from mtPC3-C or mtPC3-S cells were TRAP-stained and then counted for TRAP+ MNCs. ***p <
0.001 by one-way ANOVA with post hoc Tukey’s test. d pOCs receiving 30% mtPC3-C-CM or mtPC3-S-CM were cultured on dentin slices.
Representative confocal images of dentin surfaces (left panels) and values of pit depth and resorbed area (right panels) are presented. Scale bar =
100 μm. ***p < 0.001 by unpaired two-tailed Student’s t-test. e Western blots of c-Fos, NFATc1, and β-actin in BMM and pOCs after the indicated
number of days with 30% mtPC3-C-CM or mtPC3-S-CM. f pOCs were tested with 30% mtPC3-CM, together with the indicated concentrations of
control antibody or 4A. TRAP+ MNCs were counted. ***p < 0.001 by one-way ANOVA with post hoc Tukey’s test. Data were presented as the
mean ± SD. The full-length gels are presented in Supplementary Fig. 3 g
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osteoclasts was responsible for the mtPC3-derived
S100A4-mediated enhancement of osteoclastogenesis
(Fig. 6). Altogether, we suggest that elevated expression
of S100A4 in bone-metastatic prostate cancers contrib-
utes to cancer proliferation, migration, and EMT by
intra- and/or extracellular mechanisms. After bone-
metastasis, secreted S100A4 from metastatic-prostate
cancer cells may promote osteoclastogenesis via RAGE,
leading to bone destruction.
The overall process of cancer metastasis is compli-
cated, and various cellular events occur during this
process. At the early stage of metastasis, epithelial tumor
cells acquire the ability to detach from the primary
tumor mass and invade through the basement mem-
brane. These tumor cells then intravasate into the circu-
latory system, extravasate into a preferred distant site
depending on the type of tumor, and interact with the
metastatic environment [33, 34]. EMT is considered to
be the most critical initiation step in this process. The
clinical correlation between EMT and poor survival im-
plies the importance of EMT [35]. Loss of epithelial
properties in cancer cells by EMT not only causes cell
detachment from the primary tumor mass, promoting
intravasation, but also enhances angiogenesis, supporting
the dispersion of tumor cells through the systemic circu-
lation [36].
It has been generally appreciated that E-cadherin and
N-cadherin show an opposite expression pattern [8]. In
our study, mtPC3 cells showed no increase in N-
cadherin and snail2 while obtaining mesenchymal
properties represented by reduction of E-cadherin and
elevation of vimentin. Recently a study reported the
cases of no correlation between snail2 expression and E-
cadherin loss [37]. This report and our data suggest a
possibility that the pattern of EMT marker expression
deviates from the typical one in certain circumstances,
for example bone metastasis. The pathophysiological sig-
nificance of this interesting phenomenon should be
Fig. 6 mtPC3-CM induced osteoclastogenesis via RAGE. a Control (siCon) or RAGE siRNA (siRAGE) transfected BMMs were subjected to Western
blotting to assess protein levels of RAGE and β-actin. b pOCs transfected with siCon or siRAGE were treated with 30% mtPC3-C-CM or mtPC3-S-
CM for osteoclastogenesis. Representative TRAP-stained images (left panels) and quantification of TRAP+ MNCs (right panel). Scale bar = 100 μm.
***p < 0.001 by one-way ANOVA with post hoc Tukey’s test. c pOCs transfected with siCon or siRAGE were cultured on dentin slices with 30%
mtPC3-CM. Representative confocal images of dentine surfaces (left panels) and values of the depth of pits and resorbed area (right panels) are
presented. Scale bar = 100 μm. ***p < 0.001 by unpaired two-tailed Student’s t-test. d pOCs transfected with siCon or siRAGE were treated with
30% mtPC3-CM for 24 h and were then subjected to western blotting to assess the protein levels of RAGE, c-Fos, NFATc1, and β-actin. Data are
presented as the mean ± SD. The full-length gels are presented in Supplementary Fig. 3 h and 3i
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further explored. Although mtPC3 cells expressed less
N-cadherin and snail2 than their parent cells, our overall
data indicate that mtPC3 cells manifest mesenchymal
characteristics considering the changes in other EMT
markers (E-cadherin, β-catenin, and vimentin) and the
increased migration.
Accumulating evidence supports the role of S100A4 as
a crucial determinant of mesenchymal transition in vari-
ous types of cancer cells. In glioma stem cells, S100A4-
positive cells had tumor-initiating and sphere-forming
properties [38]. S100A4 was found to function upstream
of master EMT regulators such as Snail2 in glioblastoma
[38]. The role of S100A4 in EMT is supported by RNA
interference of S100A4 that suppressed the EMT process
in endometrial cancer cells [39]. Moreover, down-
regulation of S100A4 in breast cancer cells decreased
EMT by suppressing the expression of MMP2 [40].
However, its role in prostate cancer has not been clearly
studied yet. A previous study reported a correlation be-
tween EMT in prostate cancer cells and increased ex-
pression of S100A4 [41]. In our hands, down-regulation
of S100A4 in mtPC3 cells restored E-cadherin and β-
catenin proteins, and decreased N-cadherin and snail2
(Fig. 3). In an effort to evaluate the relevance of our re-
sults to human data, we analyzed the publicly available
data set using the GEPIA platform. In this analysis,
S100A4 was found to be expressed in various cancer
types including prostate cancer (Supplementary Fig. 2a).
In addition, the survival analysis revealed that patients
with higher S100A4 expression levels tend to have
poorer overall survival (Supplementary Fig. 2b). In line
with this survival data, it was also reported that S100A4
level was significantly higher in prostate adenocarcinoma
compared with benign prostate hyperplasia [42, 43].
These data may support our finding that S100A4 plays a
role in EMT of prostate cancer cells increasing migra-
tion potency. While further examination is required to
identify the specific mechanisms of EMT by S100A4 in
bone-metastatic prostate cancer cells, our results dem-
onstrate that S100A4 contributes to the EMT process in
prostate cancer.
In our study, the alterations in epithelial and mesen-
chymal marker proteins by S100A4 knock-down were
not observed with exogenous S100A4 treatment or with
S100A4 neutralization (Fig. 4), suggesting that intracellu-
lar, not extracellular, S100A4 promotes mesenchymal
transition of prostate tumor cells. Previous studies have
demonstrated that S100A4 interacts with non-muscle
myosin II, liprin, ezrin, and p53 in the intracellular
microenvironment [18–21]. Among these S100A4-
interacting proteins, p53 regulates EGF-mediated MMP2
transcription, which promotes EMT in breast cancer
cells [40, 44]. Beach et al. have shown that phosphoryl-
ation and isoform switching of myosin II are elevated
during EMT [45]. Yamasaki et al. and Chen et al. have
shown that liprin and ezrin, respectively, were also in-
volved in EMT [46, 47]. Thus, there is a possibility that
intracellular S100A4 promotes EMT by interacting with
these molecules in mtPC3 cells. More detailed mecha-
nisms by which S100A4 mediates EMT in prostate can-
cers warrant further investigation.
Some proteins have dual functions in intracellular and
extracellular microenvironments. For example, syntaxin2
regulates vesicle trafficking and cytokinesis in the
intracellular space, while it acts as a morphogen after se-
cretion [48–50]. Extracellular HMGB1 regulates inflam-
mation as a damage-associated molecular pattern, while
intracellular HMGB1 binds to DNA in the nucleus [51,
52]. Similarly, S100A4 also has dual intra- and extracel-
lular functions. S100A4 regulates cellular proliferation,
migration, invasion, apoptosis, and EMT in various
tumor cells. However, there have been no reports dis-
secting the intra- and extracellular roles of S100A4 in
tumor cells. In this study, we divided the functional roles
of intra- and extracellular S100A4 in bone-metastatic
prostate cancer cells using S100A4 knock-down, recom-
binant S100A4, and S100A4-neutralizing antibody. In
mtPC3 cells, intracellular S100A4 mediates proliferation
and EMT, while extracellular S100A4 contributes to os-
teoclastogenesis. Cell migration of mtPC3 cells was reg-
ulated by both intra- and extracellular S100A4.
In bone metastasis, the interaction between cancer
cells and the bone marrow niche is crucial factor deter-
mining metastatic bone phenotype such as osteolytic,
osteosclerotic, or mixed. Typically, prostate cancer
patients with bone metastasis show an osteosclerotic
bone phenotype. However, several studies have shown
that factors such as MMP-7, Runx2, and CTGF can alter
osteosclerotic bone metastasis to an osteolytic phenotype
in prostate cancers [53–55]. We found that osteoclasto-
genesis was augmented by extracellular S100A4 secreted
from mtPC3 cells (Fig. 5). The osteoclastogenesis-
promoting effect of mtPC3 could potentially lead to
osteolysis by prostate cancer cells metastasized to bone.
However, whether S100A4 up-regulation can alter the
in vivo bone phenotype by bone metastasis of prostate
cancer cells should be demonstrated in further studies.
To our knowledge, this is the first study to dissect the
intra- and extracellular functions of S100A4 in bone-
metastatic prostate cancer. Given our previous findings
regarding the inhibition of osteoblast matrix
mineralization by recombinant S100A4 treatment [56]
and on the elevated secretion of S100A4 from bone-
metastatic breast cancer cells [28], we propose that ways
to inhibit the function of S100A4 will lead to the preven-
tion of bone loss in osteolytic bone metastases. More-
over, as the elevated expression of S100A4 has been
implicated in the pathology of tissue fibrosis, rheumatoid
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arthritis and other types of cancer, a wide application of
therapeutics against S100A4 may be expected.
Conclusions
Our study demonstrates that S100A4, highly expressed
in bone-metastatic prostate cancer cells, has dual intra-
and extracellular functions. S100A4 promotes prolifera-
tion and EMT by intracellular mechanisms and, after
secretion, activates osteoclastogenesis as a ligand for the
cell surface receptor RAGE on osteoclast precursor cells.
Theses combined effects of S100A4 may be crucial for
osteolytic bone metastasis.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12885-021-07850-4.
Additional file 1: Supplementary Fig. 1. The effect of extracellular
S100A4 on LNCaP and PC3 cells. Proliferation of LNCaP (a) and PC3 (b)
cells in the presence of BSA or recombinant human S100A4 (S100A4;
2 μg/ml), was analyzed with the CCK kit.
Additional file 2: Supplementary Fig. 2. Survey of S100A4 expression
in various cancer types and relationship with patient prognosis. Based on
GEPIA online database, comparison of S100A4 expression in multiple
human cancers including prostate cancer (a) and percent of overall
survival rate according to the expression of S100A4 in prostate cancer (b)
were analyzed.
Additional file 3: Supplementary Fig. 3. The uncropped full-length
western blotting images of figures.
Abbreviations
BMM: Bone marrow-derived macrophage; CM: Conditioned medium;;
ELISA: Enzyme-linked immunosorbent assay; EMT: Epithelial-mesenchymal
transition; IL-8: Interleukin 8; OC: Osteoclast; OPG: Osteoprotegerin;
PC: Prostate cancer; PTHrP: Parathyroid hormone-related peptide;
RAGE: Receptor for advanced glycation end products; S100A4: S100 calcium-





B.K., H.K., and H.-H.K. designed the study. B.K., S.J., and H.-H.K. drafted the
manuscript. B.K. H.K., and S.J. performed the experiments. B.K., S.J., H.J.K., and
H.-H.K. analyzed data. J.-O.K., S.J., M.K.K., and M.-K.S. provided ideas and
feedback. H.J.K. and H.-H.K. critically reviewed the manuscripts. All authors
have read and approved the manuscript.
Funding
This work was supported by the National Research Foundation of Korea
(NRF) grant funded by the Korea government MSIT (NRF-2020R1A2C2010082
and NRF-2018R1A5A2024418) to H.-H. Kim and by the National Research
Foundation of Korea grant (NRF-2019R1A2C4070083) to H.J. Kim. The funding
body has no role in the design of the study; collection, analysis, and inter-
pretation of data; and in writing the manuscript.
Availability of data and materials
Data supporting the results in the article are available from the
corresponding author upon reasonable request.
Ethics approval and consent to participate
Animal experiments were performed in compliance with ethical regulations
and approved by the IACUC of Seoul National University (SNU-160105-3).
Because the GEPIA human data is accessible to the public, ethics approval is





The authors declare that they have no competing interests.
Author details
1Department of Cell and Developmental Biology, BK21 PLUS Program and
DRI, School of Dentistry, Seoul National University, 101, Daehak-ro,
Jongno-gu, Seoul, Republic of Korea 03080. 2Current address: Department of
Experimental Radiation Oncology, The University of Texas MD Anderson
Cancer Center, Houston, TX 77030, USA. 3Arthritis and Tissue Degeneration
Program, David Z. Rosensweig Genomics Research Center, Hospital for
Special Surgery, New York City, NY, USA. 4Department of Oral Physiology,
BK21 PLUS Project, and Dental and Life Science Institute, School of Dentistry,
Pusan National University, Mulgeum-eup, Yangsan, Busan 50612, South
Korea.
Received: 4 September 2020 Accepted: 27 January 2021
References
1. Sartor O, de Bono JS. Metastatic Prostate Cancer. N Engl J Med. 2018;378(7):
645–57.
2. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction.
Nat Rev Cancer. 2011;11(6):411–25.
3. Keller ET, Brown J. Prostate cancer bone metastases promote both
osteolytic and osteoblastic activity. J Cell Biochem. 2004;91(4):718–29.
4. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):
1655–64.
5. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-
beta signaling blockade inhibits PTHrP secretion by breast cancer cells and
bone metastases development. J Clin Invest. 1999;103(2):197–206.
6. Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of
the neighbourhood. Nat Rev Cancer. 2016;16(6):373–86.
7. Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, et al.
Osteoclasts control reactivation of dormant myeloma cells by remodelling
the endosteal niche. Nat Commun. 2015;6:8983.
8. Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer.
2018;18(2):128.
9. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The
transcription factor snail is a repressor of E-cadherin gene expression in
epithelial tumour cells. Nat Cell Biol. 2000;2(2):84–9.
10. Nieto MA, Cano A. The epithelial-mesenchymal transition under control:
global programs to regulate epithelial plasticity. Semin Cancer Biol. 2012;
22(5–6):361–8.
11. Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D,
et al. Epithelial-mesenchymal transition in prostate cancer: an overview.
Oncotarget. 2017;8(21):35376–89.
12. Nakazawa M, Kyprianou N. Epithelial-mesenchymal-transition regulators in
prostate cancer: androgens and beyond. J Steroid Biochem Mol Biol. 2017;
166:84–90.
13. Bitting RL, Schaeffer D, Somarelli JA, Garcia-Blanco MA, Armstrong AJ. The
role of epithelial plasticity in prostate cancer dissemination and treatment
resistance. Cancer Metastasis Rev. 2014;33(2–3):441–68.
14. Marin-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernandez PL, Pereira
MV, et al. Epithelial-to-mesenchymal transition mediates docetaxel
resistance and high risk of relapse in prostate cancer. Mol Cancer Ther.
2014;13(5):1270–84.
15. Garrett SC, Varney KM, Weber DJ, Bresnick AR. S100A4, a mediator of
metastasis. J Biol Chem. 2006;281(2):677–80.
16. Sherbet GV. Metastasis promoter S100A4 is a potentially valuable molecular
target for cancer therapy. Cancer Lett. 2009;280(1):15–30.
17. Siddique HR, Adhami VM, Parray A, Johnson JJ, Siddiqui IA, Shekhani MT,
et al. The S100A4 Oncoprotein promotes prostate tumorigenesis in a
transgenic mouse model: regulating NFkappaB through the RAGE receptor.
Genes Cancer. 2013;4(5–6):224–34.
Kim et al. BMC Cancer          (2021) 21:137 Page 12 of 13
18. Kriajevska M, Fischer-Larsen M, Moertz E, Vorm O, Tulchinsky E,
Grigorian M, et al. Liprin beta 1, a member of the family of LAR
transmembrane tyrosine phosphatase-interacting proteins, is a new
target for the metastasis-associated protein S100A4 (Mts1). J Biol Chem.
2002;277(7):5229–35.
19. Biri-Kovacs B, Kiss B, Vadaszi H, Gogl G, Palfy G, Torok G, et al. Ezrin interacts
with S100A4 via both its N- and C-terminal domains. PLoS One. 2017;12(5):
e0177489.
20. Li ZH, Bresnick AR. The S100A4 metastasis factor regulates cellular motility
via a direct interaction with myosin-IIA. Cancer Res. 2006;66(10):5173–80.
21. Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, Kruse C,
et al. Tumor suppressor p53 protein is a new target for the metastasis-
associated Mts1/S100A4 protein: functional consequences of their
interaction. J Biol Chem. 2001;276(25):22699–708.
22. Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M,
Tulchinsky E, et al. The metastasis-associated Mts1(S100A4) protein could
act as an angiogenic factor. Oncogene. 2001;20(34):4685–95.
23. Novitskaya V, Grigorian M, Kriajevska M, Tarabykina S, Bronstein I, Berezin V,
et al. Oligomeric forms of the metastasis-related Mts1 (S100A4) protein
stimulate neuronal differentiation in cultures of rat hippocampal neurons. J
Biol Chem. 2000;275(52):41278–86.
24. Belot N, Pochet R, Heizmann CW, Kiss R, Decaestecker C. Extracellular
S100A4 stimulates the migration rate of astrocytic tumor cells by modifying
the organization of their actin cytoskeleton. Biochim Biophys Acta. 2002;
1600(1–2):74–83.
25. Herwig N, Belter B, Wolf S, Haase-Kohn C, Pietzsch J. Interaction of
extracellular S100A4 with RAGE prompts prometastatic activation of A375
melanoma cells. J Cell Mol Med. 2016;20(5):825–35.
26. Medapati MR, Dahlmann M, Ghavami S, Pathak KA, Lucman L, Klonisch T,
et al. RAGE mediates the pro-migratory response of extracellular S100A4 in
human thyroid Cancer cells. Thyroid. 2015;25(5):514–27.
27. Dahlmann M, Okhrimenko A, Marcinkowski P, Osterland M, Herrmann P,
Smith J, et al. RAGE mediates S100A4-induced cell motility via MAPK/ERK
and hypoxia signaling and is a prognostic biomarker for human colorectal
cancer metastasis. Oncotarget. 2014;5(10):3220–33.
28. Kim H, Kim B, Kim SI, Kim HJ, Ryu BY, Chung J, et al. S100A4 released from
highly bone-metastatic breast cancer cells plays a critical role in osteolysis.
Bone research. 2019;7(1):1–13.
29. Kim H, Lee YD, Kim HJ, Lee ZH, Kim HH. SOD2 and Sirt3 control
osteoclastogenesis by regulating mitochondrial ROS. J Bone Miner Res.
2017;32(2):397–406.
30. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer
and normal gene expression profiling and interactive analyses. Nucleic
Acids Res. 2017;45(W1):W98–W102.
31. Hou S, Tian T, Qi D, Sun K, Yuan Q, Wang Z, et al. S100A4 promotes lung
tumor development through beta-catenin pathway-mediated autophagy
inhibition. Cell Death Dis. 2018;9(3):277.
32. Zhu Y, Zhou Y, Zhou X, Guo Y, Huang D, Zhang J, et al. S100A4 suppresses
cancer stem cell proliferation via interaction with the IKK/NF-kappaB
signaling pathway. BMC Cancer. 2018;18(1):763.
33. Stuelten CH, Parent CA, Montell DJ. Cell motility in cancer invasion and
metastasis: insights from simple model organisms. Nat Rev Cancer. 2018;
18(5):296–312.
34. Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al.
Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer.
2017;17(5):302–17.
35. Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al.
EMT and tumor metastasis. Clin Transl Med. 2015;4:6.
36. Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, Yilmaz M, et al. VEGF-
mediated angiogenesis links EMT-induced cancer stemness to tumor
initiation. Cancer Res. 2014;74(5):1566–75.
37. Sterneck E, Poria DK, Balamurugan K. Slug and E-cadherin: stealth
accomplices? Front Mol Biosci. 2020;7:138.
38. Chow KH, Park HJ, George J, Yamamoto K, Gallup AD, Graber JH, et al.
S100A4 is a biomarker and regulator of glioma stem cells that is critical for
mesenchymal transition in glioblastoma. Cancer Res. 2017;77(19):5360–73.
39. Hua T, Liu S, Xin X, Cai L, Shi R, Chi S, et al. S100A4 promotes endometrial
cancer progress through epithelial-mesenchymal transition regulation.
Oncol Rep. 2016;35(6):3419–26.
40. Xu H, Li M, Zhou Y, Wang F, Li X, Wang L, et al. S100A4 participates in
epithelial-mesenchymal transition in breast cancer via targeting MMP2.
Tumour Biol. 2016;37(3):2925–32.
41. Amatangelo MD, Goodyear S, Varma D, Stearns ME. C-Myc expression and
MEK1-induced Erk2 nuclear localization are required for TGF-beta induced
epithelial-mesenchymal transition and invasion in prostate cancer.
Carcinogenesis. 2012;33(10):1965–75.
42. Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H. Differential
expression of S100A2 and S100A4 during progression of human prostate
adenocarcinoma. J Clin Oncol. 2003;21(1):106–12.
43. Kwon Y-W, Chang IH, Kim KD, Kim YS, Myung S-C, Kim M-K, et al.
Significance of S100A2 and S100A4 expression in the progression of
prostate adenocarcinoma. Korean J Urol. 2010;51(7):456–62.
44. Staun-Ram E, Goldman S, Shalev E. p53 mediates epidermal growth factor
(EGF) induction of MMP-2 transcription and trophoblast invasion. Placenta.
2009;30(12):1029–36.
45. Beach JR, Hussey GS, Miller TE, Chaudhury A, Patel P, Monslow J, et al.
Myosin II isoform switching mediates invasiveness after TGF-β-induced
epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108(44):
17991–6.
46. Chen MJ, Gao XJ, Xu LN, Liu TF, Liu XH, Liu LX. Ezrin is required for
epithelial-mesenchymal transition induced by TGF-β1 in A549 cells. Int J
Oncol. 2014;45(4):1515–22.
47. Yamasaki A, Nakayama K, Imaizumi A, Kawamoto M, Fujimura A, Oyama Y,
et al. Liprin-α4 as a possible new therapeutic target for pancreatic cancer.
Anticancer Res. 2017;37(12):6649–54.
48. Abonyo BO, Gou D, Wang P, Narasaraju T, Wang Z, Liu L. Syntaxin 2 and
SNAP-23 are required for regulated surfactant secretion. Biochemistry. 2004;
43(12):3499–506.
49. Low SH, Li X, Miura M, Kudo N, Quiñones B, Weimbs T. Syntaxin 2 and
endobrevin are required for the terminal step of cytokinesis in mammalian
cells. Dev Cell. 2003;4(5):753–9.
50. Radisky DC, Hirai Y, Bissell MJ. Delivering the message: epimorphin
and mammary epithelial morphogenesis. Trends Cell Biol. 2003;13(8):
426–34.
51. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear
weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331–42.
52. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA
by nuclear protein HMG1. Science. 1989;243(4894 Pt 1):1056–9.
53. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, et al. MMP-7
promotes prostate cancer-induced osteolysis via the solubilization of RANKL.
Cancer Cell. 2005;7(5):485–96.
54. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, et al.
Runx2 association with progression of prostate cancer in patients:
mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Oncogene. 2010;29(6):811–21.
55. Kim B, Kim H, Jung S, Moon A, Noh DY, Lee ZH, et al. A CTGF-RUNX2-RANKL
axis in breast and prostate cancer cells promotes tumor progression in
bone. J Bone Miner Res. 2020;35(1):155–66.
56. Kim H, Lee YD, Kim MK, Kwon JO, Song MK, Lee ZH, et al. Extracellular
S100A4 negatively regulates osteoblast function by activating the NF-
kappaB pathway. BMB Rep. 2017;50(2):97–102.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kim et al. BMC Cancer          (2021) 21:137 Page 13 of 13
